Insider Ledger
OKYO Pharma Ltd (OKYO) insider buying and SEC filings
OKYO Pharma Ltd · CIK 1849296
Tracked: Forms 3/4/5, 8-K, NT · Limited coverage: files 6-K/20-F, not covered in v1 · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
Insider activity in the last 12 months
Bought
$119K
Insiders who bought
3
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 27, 2026 | Open-market purchase Amended filing | Rajkumar V. Patil (Chief Scientific Officer) bought 3,363 shares at $1.49 ($5K) in an open-market purchase. Holdings up 20% to 20,030 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 29. | SEC filing Filed Aug 7, 2026 |
| Jul 22, 2026 | Open-market purchase Amended filing | Robert John Dempsey (CEO and Director) bought 15,000 shares at $1.54 ($23K) in an open-market purchase. New position of 15,000 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 23. | SEC filing Filed Aug 7, 2026 |
| Jul 21, 2026 | Open-market purchase Amended filing | John P. Brancaccio (Director) bought 5,000 shares at $1.48 ($7K) in an open-market purchase. Holdings up 17% to 35,201 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 23. | SEC filing Filed Aug 7, 2026 |
| Jul 21, 2026 | Open-market purchase Amended filing | Gary S. Jacob (Chief Development Officer and Director) bought 3,500 shares at $1.40 ($5K) in an open-market purchase. Holdings up 3% to 112,420 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 23. | SEC filing Filed Aug 7, 2026 |
| Jul 21, 2026 | Open-market purchase Amended filing | Flavio Mantelli (Chief Medical Officer) bought 20,000 shares at $1.40 ($28K) in an open-market purchase. New position of 20,000 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 22. | SEC filing Filed Aug 7, 2026 |
| Jul 21, 2026 | Open-market purchase Amended filing | Gabriele M. Cerrone (Director and 10% owner) bought 22,500 shares indirectly at $1.45 ($33K) in an open-market purchase. Indirect holdings up <1% to 10,873,916 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 23. | SEC filing Filed Aug 7, 2026 |
| Jul 20, 2026 | Open-market purchase Amended filing | Gabriele M. Cerrone (Director and 10% owner) bought 25,000 shares indirectly at $1.40 ($35K) in an open-market purchase. Indirect holdings up <1% to 10,851,416 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Jul 21. | SEC filing Filed Aug 7, 2026 |
12 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
3 insiders bought in 30 days
$119K in purchases since Jul 20, 2026 · Purchases traded Jul 20, 2026 to Jul 22, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Gabriele M. Cerrone (Director) | $35K | Jul 20, 2026 | SEC filing |
| Gabriele M. Cerrone (Director) | $33K | Jul 21, 2026 | SEC filing |
| Flavio Mantelli (Chief Medical Officer) | $28K | Jul 21, 2026 | SEC filing |
| Robert John Dempsey (CEO) | $23K | Jul 22, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow OKYO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.